目的：比较利培酮联合舒血宁与利培酮联合安慰剂治疗慢性精神分裂症的疗效和安全性。方法慢性精神分裂症患者82例，随机分为利培酮联合舒血宁治疗组（研究组）和利培酮联合安慰剂治疗组（对照组），各41例。使用阳性与阴性症状评定量表（PANSS）和精神药物副反应量表（TESS）评定临床疗效和不良反应。治疗前和治疗第4、8、12周末评估PANSS，治疗前和治疗12周末评估TESS。结果研究组有效率46.34%，对照组为21.95%，两组比较差异有统计学意义（P<0.05）。研究组低血压、心动过速发生率高于对照组，迟发性运动障碍和心电图异常发生率低于对照组（P<0.05）。结论利培酮联合舒血宁治疗慢性精神分裂症疗效优于单用利培酮，不良反应少。%Objective To compare the efficacy and safety of risperidone combined with Shuxuening versus risperidone combined with placebo in the treatment of patients with chronic schizophrenia. Methods Eighty-two patients admitted in Tongde Hospital were randomly divided into risperidone combined with Shuxuening group (study group, n=41) or risperidone combined with placebo group(control group, n=41). Drugs were given for 12 weeks. Positive and Negative Syndrome Scale(PANSS) and Treatment Emergent Symptom Scale(TESS) were as-sessed in two groups before treatment and at the 4th, 8th and 12th week during treatment. Results The effective rate was 46.34% and 21.95% in study group and control group, respectively, with a significant difference between them(P<0.05). Compared with control group, the incidence of tachycardia and hypotension was higher and the inci-dence of tardive dyskinesia and abnormal electrocardiographic pattern was lower in study group(all P<0.05). Con-clusion Risperidone combined with Shuxuening is more effective in treatment of chronic schizophrenia than risperidone combined with placebo does, with less adverse events.
展开▼
